Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Tatyana Feldman, MD, Larysa Gromko, MD, Ewelina A Protomastro, MS, Lina Starovoitova, BS, Anthony R. Mato, MD MSCE, Chad Glisch, Mona Sadekh, MD, Benjamin Schoener, MD, Susan Stives, APN, Marisa Valentinetti, RN, Mary Timberg, APN, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Xiao Yang, MD PhD, Alan P Skarbnik, MD, Andre Goy, MD MS

Blood (2014) 124 (21): 1307.

https://doi.org/10.1182/blood.V124.21.1307.1307

Published: 2014

Journal Articles

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Blood (2014) 124 (21): 3033.

https://doi.org/10.1182/blood.V124.21.3033.3033

Published: 2014

Journal Articles

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Tatyana Feldman, MD, Anthony R Mato, MD, Michele L. Donato, MD, Scott D Rowley, MD, Stuart L. Goldberg, MD, Carolanne Carini, RN, Marisa Valentinetti, RN, Judith Smith, RN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Susan Stives, APN, Mary Timberg, RN, MSN, OCN, NP-C, Ewelina A Protomastro, BA, Joshua R. Richter, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, David S. Siegel, MD, PhD, Andre Goy, MD

Blood (2012) 120 (21): 3710.

https://doi.org/10.1182/blood.V120.21.3710.3710

Published: 2012

Journal Articles

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Anthony R Mato, MD, Andre Goy, MD, Kathryn Waksmundzki, BS, Tatyana Feldman, MD, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Coleen Bejot, MSN, NP-C, Gabriella Gadaleta, RN, APN-C, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Katherine Facchin, RN, John P. Leonard, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tsiporah B Shore, Usama Gergis, MD, Morton Coleman, MD, Rebecca Elstrom, MD

Blood (2012) 120 (21): 4269.

https://doi.org/10.1182/blood.V120.21.4269.4269

Published: 2012

Journal Articles

Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome

Anthony R Mato, MD, James Greenberg, BS, Mary E Putt, PhD, ScD, K. Stephen Suh, PhD, Yvonne Remache, BA, BSN, Tania Zielonka, RDC, Kathryn Waksmundzki, BS, Ewelina A Protomastro, BA, Susan Stives, APN, Tatyana Feldman, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, M.D. Ph.D, Kar Fai Chow, MD, Alex Campaiola, BSN, Andrew L Pecora, MD, Andre Goy, MD

Blood (2012) 120 (21): 1579.

https://doi.org/10.1182/blood.V120.21.1579.1579

Published: 2012

Journal Articles

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Anthony R Mato, MD, Kathryn Waksmundzki, BS, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Theresa Amatucci, BS, Maria Rosario, Stuart L. Goldberg, MD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L. Donato, MD, Mary Timberg, RN, MSN, OCN, NP-C, Melissa F Baker, APN, Pam Sutherland, MSN, CRNP, Phyllis McKiernan, MSN, CRNP, Andrew L Pecora, MD, Andre Goy, MD

Blood (2012) 120 (21): 3120.

https://doi.org/10.1182/blood.V120.21.3120.3120

Published: 2012

Journal Articles

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Anthony R Mato, MD, Ewelina A Protomastro, BA, Tania Zielonka, RDC, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Pritish K. Bhattacharyya, MD, Mary Timberg, RN, MSN, OCN, NP-C, Susan Stives, APN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Andre Goy, MD

Blood (2012) 120 (21): 3658.

https://doi.org/10.1182/blood.V120.21.3658.3658

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only